











































Opposing Roles of apolipoprotein E in aging and
neurodegeneration
Citation for published version:
Hudry, E, Klickstein, J, Cannavo, C, Jackson, R, Muzikansky, A, Gandhi, S, Urick, D, Sargent, T, Wrobleski,
L, Roe, AD, Hou, SS, Kuchibhotla, KV, Betensky, RA, Spires-Jones, T & Hyman, BT 2019, 'Opposing Roles
of apolipoprotein E in aging and neurodegeneration', Life Science Alliance, vol. 2, no. 1.
https://doi.org/10.26508/lsa.201900325
Digital Object Identifier (DOI):
10.26508/lsa.201900325
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 23. Jul. 2021
Research Article
Opposing Roles of apolipoprotein E in aging and
neurodegeneration
Eloise Hudry1 , Jacob Klickstein1, Claudia Cannavo2, Rosemary Jackson2, Alona Muzikansky3, Sheetal Gandhi1,
David Urick1, Taylie Sargent1 , Lauren Wrobleski1, Allyson D Roe1, Steven S Hou1, Kishore V Kuchibhotla4,
Rebecca A Betensky3, Tara Spires-Jones2, Bradley T Hyman1
Apolipoprotein E (APOE) effects on brain function remain con-
troversial. Removal of APOE not only impairs cognitive functions
but also reduces neuritic amyloid plaques in mouse models of
Alzheimer’s disease (AD). Can APOE simultaneously protect and
impair neural circuits? Here, we dissociated the role of APOE in AD
versus aging to determine its effects on neuronal function and
synaptic integrity. Using two-photon calcium imaging in awake
mice to record visually evoked responses, we found that genetic
removal of APOE improved neuronal responses in adult APP/
PSEN1 mice (8–10 mo). These animals also exhibited fewer
neuritic plaques with less surrounding synapse loss, fewer
neuritic dystrophies, and reactive glia. Surprisingly, the lack of
APOE in aged mice (18–20 mo), even in the absence of amyloid,
disrupted visually evoked responses. These results suggest a
dissociation in APOE’s role in AD versus aging: APOE may be
neurotoxic during early stages of amyloid deposition, although
being neuroprotective in latter stages of aging.
DOI 10.26508/lsa.201900325 | Received 29 January 2019 | Revised 5 February
2019 | Accepted 6 February 2019 | Published online 13 February 2019
Introduction
Apolipoprotein E (APOE) in the central nervous system (CNS) has
been the focus of study for two reasons: it is the most abundantly
expressed apolipoprotein in the CNS (Bjorkhem & Meaney, 2004;
Huang & Mahley, 2014), and inheritance of the E4 allele of the APOE
gene profoundly impacts the risk for Alzheimer’s disease (AD),
exacerbating amyloid deposition and worsening cognition and
synapse loss. We, therefore, sought to examine the effect of APOE
depletion on neuronal function and synaptic integrity in adult or
aged mice in both physiological and pathophysiological contexts.
As the primary CNS apolipoprotein, APOE is responsible for much
of the regulation of the brain lipid metabolism, particularly the
transfer of cholesterol and phospholipids from glial cells to
neurons (Boyles et al, 1985; Pitas et al, 1987; Pfrieger & Ungerer,
2011). During adulthood, neurons rely on cholesterol from glial cells
for many processes; thus APOE plays an important role in modu-
lating synapse growth, stabilization, and renewal in a physiological
context (Holtzman & Fagan, 1998; Mauch et al, 2001). APOE is also
involved in removing cholesterol and lipids from the CNS, therefore
controlling the clearance of cellular debris and promoting
remyelination in the aged CNS and some neurodegenerative dis-
eases (Mahley, 1988; Zlokovic, 2011; Cantuti-Castelvetri et al, 2018).
Other functions of APOE in the neural tissue include buffering
oxidative stress (Evola et al, 2010; Chen et al, 2015) and preserving
the integrity of the blood–brain barrier (Fullerton et al, 2001; Hafezi-
Moghadam et al, 2007; Nishitsuji et al, 2011), further emphasizing the
pivotal role of APOE in maintaining brain homeostasis.
Previous studies have observed that a complete lack of APOE in
murine models leads to cognitive impairment when compared with
wild-typemice (Gordon et al, 1995; Masliah et al, 1997; Kitamura et al,
2004; Trommer et al, 2004; Yang, Gilley et al, 2011a; Zerbi et al, 2014),
whereas others failed to detect similar deficits (Hartman et al, 2001;
Bour et al, 2008). A recent case study of a 40-yr-old man with a
complete absence of APOE expression initially reported normal
cognitive function (despite dramatic hypercholesterolemia [Mak
et al, 2014]), but a second in-depth evaluation showed some evi-
dence of cognitive impairment (Cullum & Weiner, 2015). Whether
these discrepancies result from the use of different cognitive tasks
or from the age of the animals and subjects included in each study
is unclear, but there is no doubt that further investigation of the
specific impact of APOE on neuronal function in vivo remains an
important unmet goal.
In the context of disease, APOE was identified more than two
decades ago as a significant modulator of the risk for late-onset AD
(Wisniewski & Frangione, 1992; Corder et al, 1993, 1994; West et al,
1994; Hyman et al, 1996; Lippa et al, 1997). APOE is a well-established
partner of amyloid β (Aβ) peptides, catalyzing Aβ oligomerization,
aggregation in the parenchyma (Holtzman et al, 2000; Fagan et al,
2002; Hashimoto et al, 2012), clearance (Deane et al, 2008;
1Alzheimer Research Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA 2Centre for Discovery Brain
Sciences, UK Dementia Research Institute, and Edinburgh Neuroscience, The University of Edinburgh, Edinburgh, UK 3Department of Biostatistics, Harvard T.H. Chan
School of Public Health, Boston, MA, USA 4Johns Hopkins University, Baltimore, MD, USA
Correspondence: ehudry@mgh.harvard.edu
© 2019 Hudry et al. https://doi.org/10.26508/lsa.201900325 vol 2 | no 1 | e201900325 1 of 16
on 14 November, 2019life-science-alliance.org Downloaded from 
http://doi.org/10.26508/lsa.201900325Published Online: 13 February, 2019 | Supp Info: 
Castellano et al, 2011; Hudry et al, 2013), and recruitment to the
synapse (Koffie et al, 2012). More recently, APOE has also been
identified as a molecular trigger of the amyloid-dependent neu-
roinflammatory response via its role as a ligand for the triggering
receptor expressed on myeloid cells 2 (TREM2) (Atagi et al, 2015; Yeh
et al, 2016). Disruption of the murine apoE gene in AD transgenic
models significantly delays the formation of the so-called “dense
core” Thio-S–positive amyloid plaques (Bales et al, 1997; Irizarry,
Cheung et al, 2000a), even though substantial load of diffuse
amyloid and elevated concentrations of soluble Aβ peptides re-
main in the parenchyma (Irizarry, Rebeck et al, 2000b). These results
suggest that a complete lack of APOE may have a beneficial impact
on amyloidopathy, a hypothesis recently validated using an ap-
proach by antisense oligonucleotide-based knockdown of APOE in
mouse models of amyloidosis (Huynh et al, 2017). However, the
consequences of APOE genetic disruption on neuronal function and
synaptic integrity are still being debated. The question remains if
APOE can simultaneously protect and impair brain homeostasis.
The present study aims to examine both APOE’s role in normal
physiology and in Aβ-induced neurotoxicity. To do so, we investi-
gate how APOE affects neuronal function and synaptic integrity
rather than only focusing on amyloid changes.
In this study, we used two-photon calcium imaging in the visual
cortex tomeasure visually evoked neuronal responses (Andermann
et al, 2011; Grienberger et al, 2012; Kuchibhotla et al, 2014) and array
tomography to assess synapse density at a single-synapse reso-
lution (Koffie et al, 2012; Tai et al, 2012; Kay et al, 2013). We sys-
tematically evaluated the impact of the presence or absence of
APOE on neuronal function and synaptic integrity in mice that
develop plaques (APP/PSEN1 mice expressing both the human
mutated Amyloid precursor protein, APP, and presenilin-1, PSEN1,
genes) and those without increased amyloidosis (wild-type). Our
results demonstrate that in the context of amyloid pathology, APOE
enables Aβ-dependent neuronal dysfunction and synaptotoxicity
and a dramatic protective effect is observed by ApoEnull. By contrast,
APOE also appears as an important factor to preserve brain function
during aging, even in the absence of amyloid deposition. These
findings, therefore, dissociate APOE’s role towards amyloid neuro-
pathological changes versus normal aging and warrant further
consideration of the impact of APOE on neuronal function in addition
to its effect on amyloid.
Results
Disruption of visually evoked responses in transgenic mice model
of amyloidosis
To establish how APOE modulates neuronal function and amyloid-
dependent dysfunction in vivo, we recorded neuronal calcium
transients triggered by visual stimulation in wild-type, APOEnull,
APP/PSEN1, and APP/PSEN1/APOEnull mice (Fig 1A). The study of
neuronal dysfunction in the visual cortex is relevant to AD, as
deficits in central sensory processing have been reported in the
disease, particularly at advanced stages (Cronin-Golomb et al, 1991;
Bublak et al, 2011). The visual area V1 is also easily accessible for
intra-vital calcium imaging (Andermann et al, 2011) and constitutes
the output of a relatively simple circuitry downstream of the retina
and the lateral geniculate nucleus within the thalamus (Seabrook
et al, 2017), therefore facilitating the recording of neuronal re-
sponses to well-controlled sensory stimuli. In addition, two age
groups were included in our study (8–10-mo-old “adult” mice and
Figure 1. Experimental setting for in vivo recording
of visually evoked responses.
(A) Calcium transients were recorded in the primary
visual cortex V1 while presenting eight different
drifting gratings to the contralateral eye (screen–eye
distance, 20 cm; screen-midline angle, 60 Åã). The
lower panel shows a representative in vivo two-
photon image of AAV-CBA-YC signal detected in
neurons onemonth after AAV stereotaxic injection. (B)
Examples of averaged traces for three neurons
individually selected in (A) show that the responses
are highly heterogeneous within the same field of
view, from nonresponsive (cell #3) to broadly
responsive (cell #2) and neuron responding
selectively to a particular orientation of the stimulus
(cell #1). Bar graph: 100 μm.
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18–20-mo-old “aged” mice) to determine the impact of age, ge-
notype, and the interaction of both parameters (Fig S1A). We could
record robust neuronal responses to the visual stimuli in all ex-
perimental groups. In our stimulation protocol, responding cells
were detected in the primary visual area (mean = 6.89 ± 1.05% for
wild-type littermates; 13.76 ± 2.13% for the APP/PS1; 9.75 ± 2.3% for
the APOEnull; and 10.58 ± 1.53% for the APP/PS1/APOEnull mice, Fig
S1A and B). Within the same field of view, a wide range of different
response patterns was observed, including nonresponsive cells (no
correlation between calcium transients and visual stimulation), broadly
responsive cells (increased firing simultaneously to any stimulus), and
visually tuned neurons responding to a specific orientation and/or
direction of the visual stimulus (Fig 1B). There was no statistical dif-
ference between the percentage of “responding cells” among the
experimental groups (Fig 2A, P = 0.0682), with variability depending
whether or not the region of interest (ROI) considered was exactly
located within the primary visual cortex area or at the edge of it (Fig S2).
When establishing our protocol, we observed that in contrast to
the broadly tuned cells that responded to any stimuli, occasional
neurons systematically fired when the stimuli went off (which we
defined as “off-responders,” Fig 2B), a phenomenon previously
described when recording visual responses in awake animals (Jin
et al, 2008; Liang et al, 2008). When we calculated the percentage of
“off-responding” neurons in comparison with the overall number of
responding cells within the same fields of view, we observed a
significant increased proportion of “off-responders” specifically in
APP/PSEN1 mice (16.57 ± 4.68%, Kruskal–Wallis test, P = 0.0068,
Fig 2C), which tended to be exacerbated in aged as compared with
adult transgenic APP/PSEN1 animals (even though the difference
between “adult” and “aged” APP/PSEN1 did not reach statistical
significance, Fig S3). Intriguingly, the percentage of off-responding
neurons was much lower in all the other groups considered (wild-
type: 4.32 ± 1.27%; APOEnull: 4.68 ± 1.19%; and APP/PSEN1/APOEnull: 3.2 ±
0.84%), and especially in APP/PSEN1/APOEnull mice lacking apoe
expression, suggesting that APOEnull mice normalizes an alteration
from normal physiology observed in APP/PSEN1 mice.
Apoe genetic ablation in adult APP/PSEN1 mice restores visual
selectivity but sensitizes the brain towards age-associated neu-
ronal dysfunction.
To gain further insight into the functional integrity of the visual
network between wild-type, APOEnull, APP/PSEN1, and APP/PSEN1/
APOEnull mice, we then compared the direction selectivity index
(DSI) and orientation selectivity index (OSI) between these groups
(Fig 3A and B). DSI and OSI represent quantifiable measurements of
the ability of visual neurons to respond to a principal orientation or
direction of a visual stimulus as compared with others, and higher
DSI and OSI values correspond to a more specific tuning to the
stimulation. Of importance, this functional feature (the tuning of
visual neurons to stimulation) has been previously reported to be
impaired in mouse models of amyloidopathy (Grienberger et al,
2012). After fitting a linear mixed model with “genotype” and “age”
as fixed effect and “mouse” as random effect, we demonstrated that
the log-adjusted DSI and OSI were significantly associated with the
genotype (P = 0.0013 for DSI and P = 0.0076 for OSI) and with the age
of the mice (P = 0.0325 for DSI and P = 0.0068 for OSI). In particular,
the average of both DSI and OSI was lower in APP/PSEN1 mice as
compared with wild-type animals (P = 0.0002 and P = 0.0008, re-
spectively), therefore demonstrating impaired tuning to visual
Figure 2. “Responders” and “off-responders”
proportions.
(A) Scatter dot plot representing the percentage of
neurons responding to visual stimulation among all
neurons analyzed in each animal. (B) Representative
traces or visually evoked neuronal responses showing
the concomitant presence of broad and off-
responding cells in the same field of view during the
same imaging session. (C) Scatter dot plot of the
percentage of “off-responding” cells across genotypes
(calculated accordingly to the number of responsive
neurons within the same fields of view). n = 18 wild-
type, n = 13 APOEnull, n = 18 APP/PSEN1, and n = 16 APP/
APOEnull mice (adult and old cohorts); Kruskal–Wallis
test followed by post hoc Dunn’s Multiple comparison
test; *P < 0.05.
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stimulation in this model of amyloidosis. This was not the case
between the control and APP/PSEN1/APOEnull groups (P = 0.4091
and P = 0.1584). These results, therefore, demonstrated that the
absence of APOE largely abrogates Aβ-dependent neuronal dys-
function in a mouse model of amyloidosis. However, APOEnull mice
still showed a mild decreased OSI average when compared with
wild-type controls (P = 0.0294), implying that the complete lack of
APOE itself can impact tuning performances.
Pair-wise comparisons between adult and aged mice (Fig S4A)
revealed more prominent age-dependent decreases of the OSI
values in APP/PSEN1/APOEnull (P = 0.037), with a similar but non-
significant decrease in APOEnull (P = 0.109) mice. No age-dependent
change was detected for the control or APP/PSEN1 groups, which
respectively presented with high or low OSI means across the life-
span of themice. The DSI values showed fewer differenceswith only a
significant decreased average of the DSI detected in aged APP/PSEN1
mice (P = 0.0445). The higher sensitivity of OSI to discriminate
changes in visual tuning canbe explainedby the fact that the OSI was
calculated based on the tuning discrimination between the “favorite”
orientation as compared with three other orientations, whereas the
DSI was calculated based on preferential firing for one direction as
compared with the opposite one. When compared with age-matched
littermates (Fig S4B), both adult and aged APP/PSEN1 mice were
significantly impaired for OSI and DSI (P = 0.011 for DSI and P = 0.0012
for OSI when comparing adult APP/PSEN1 and littermates; and P =
0.022 for DSI and P = 0.042 for OSI when comparing aged APP/PSEN1
and littermates). However, only the OSI values were significantly
diminished in aged APOEnull mice as compared with aged controls
(P = 0.04). The averaged OSI in aged APP/PSEN1/ApoEnull mice was
also lower than wild-type animals, but this difference did not reach
significance (P = 0.084). These results demonstrated early and
pronounced neuronal dysfunction in mice model of Aβ amyloidosis,
a phenotype significantly improved in adult mice lacking APOE.
However, age-dependent deficits were also detected in older
APOEnull and, to a lesser extent, APP/PSEN1/APOEnull mice. We
concluded that APOE is a necessary factor participating in amyloid-
dependent loss of network integrity, although complete lack of APOE
independently triggers mild neuronal dysfunction with age.
Apoe genetic ablation does not impact global amyloid burden but
affects the aggregation state of Aβ
To evaluate how the “rescue effect” observed in mice lacking APOE
correlated with the level of amyloid pathology, we performed a
Figure 3. Tuning to visual stimuli in wild-type,
APOEnull, APP/PSEN1, and APP/PSEN1/APOEnull mice.
(A) Scatter dot plots representing the DSI (left panel)
and OSI (right panel) calculated after recording
visually evoked response in wild-type, APOEnull, APP/
PSEN1, and APP/PSEN1/APOEnull mice. (B) Cumulative
distributions of DSI and OSI calculated for all
responding neurons showing a shift towards an
increased proportion of poorly tuned neurons in APP/
PSEN1 as compared with the other genotypes, with the
exception of the OSI distribution in APOEnull mice. n =
18 wild-type, n = 13 APOEnull, n = 18 APP/PSEN1, and n =
16 APP/APOEnull mice (adult and old cohorts); linear
mixed model after log-transformation of the data; *P <
0.05.
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stereological analysis of the load and density of amyloid plaques in
the cortex of APP/PSEN1 and APP/PSEN1/APOEnull mice. Conven-
tional anti-Aβ immunolabeling detecting all amyloid aggregates
revealed that neither the burden nor the density of deposits was
significantly different between APP/PSEN1 and APP/PSEN1/APOE-
null (Fig 4A–C). By contrast, a dramatic decrease in the amount of
fibrillar deposits stained by Methoxy-XO4 was observed in mice
lacking APOE (Fig 5D; P < 0.0001 and P = 0.0004, respectively, for
Methoxy load and density between APP/PSEN1 and APP/PSEn1/
APOEnull mice), in agreement with previous reports showing that
APOE significantly affects the aggregation state of Aβ neurotoxic
species (Irizarry et al, 2000a; Holtzman et al, 2000; Fagan et al, 2002).
Figure 4. Amyloid pathology in APP/PSEN1 and
APP/PSEN1/APOEnull mice.
(A) Representative images of the global amount of
amyloid in the cortex of APP/PSEN1 and APP/PSEN1/
APOEnull mice at 10-mo old after anti-Aβ
immunostaining (IH). As shown in the lower panels,
the overall load of amyloid was comparable between
genotypes, but the amount of dense-core plaques
detected with Methoxy-XO4 was greatly diminished in
the absence of APOE. (B) Scatter dot plot representing
the stereological quantification of amyloid load in
APP/PSEN1 and APP/PSEN1/APOEnull animals
(including both adult and aged cohorts) after anti-Aβ
immunostaining or Methoxy-XO4 labeling. (C) Scatter
dot plots representing the stereological quantification
of plaque density in APP/PSEN1 and APP/PSEN1/
APOEnull animals. (D) The ratios of IH/Methoxy
calculated per mouse showed that the amyloid
deposits are mostly diffuse in APP/PSEN1/APOEnull
mice as compared with APP/PSEN1. (E) The
biochemical quantification of the concentrations of
TBS-soluble Aβ40 and Aβ42 revealed lower levels of
Aβ peptides in mice devoid of APOE as compared with
APP/PSEN1 mice (both age groups pooled together).
(F) A parallel result was observed when quantifying
the levels of FA Aβ40 and Aβ42. (G) A similar difference
was observed when the concentration of Aβ oligomers
was measured from TBS brain extracts. Scale bar =
1,000 μm. n = 10 to 18 mice/group; unpaired t test; *P <
0.05, **P < 0.001, ***P < 0.0005.
APOE’s impact on neuron function Hudry et al. https://doi.org/10.26508/lsa.201900325 vol 2 | no 1 | e201900325 5 of 16
Figure 5. Ab-dependent synaptic loss and neuritic
dystrophies in adult APP/PSEN1 and APP/PSEN1/
APOEnull mice.
(A) Representative images of array tomography
ribbons after immunostaining for Ab (1C22),
presynaptic terminals (antisynapsin I, red),
postsynaptic densities (anti-PS95, green), and nuclei
(DAPI, blue). It is possible to appreciate how diffuse is
the amyloid in the brain of APP/APOEnull mouse as
compared with the compact staining observed in the
APP mouse. Scale bar = 10 μm. (B) Scatter dot plots
summarizing the density of PSD95 (left panel) and
synapsin (right panel)-positive puncta in the cortex of
wild-type, APOEnull, APP/PSEN1, and APP/PSEN1/
APOEnull mice. A significant decrease in synaptic
density was only observed in the close vicinity of
amyloid plaques in AD transgenic mice. n = 6 mice/
group (10–12 mo “adult” cohort); Two-way ANOVA and
Tukey’s post hoc test. *P < 0.05 and ***P < 0.0001. (C)
Representative images of neuritic dystrophies
(arrows) around amyloid plaques observed in APP/
PSEN1 and APP/PSEN1/APOEnull mice, showing that
most sprouting axons are found in mice expressing
endogenous murine apoE. Scale bar = 50 μm. (D)
Scatter dot plot summarizing the stereological
quantification of the number of dystrophies observed
per area of amyloid (evaluated by immunohistological
staining). n = 6 mice per group (10–12 mo “adult”
cohort); Mann–Whitney test. *P < 0.005.
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Consequently, the ratio of amyloid load between “all deposits” and
dense core plaques was significantly higher in APP/PSEN1/APOEnull
as compared with APP/PSEN1 mice (Fig 4D). Within each genotype,
the amyloid load progressed between adult and aged mice, but the
increase in Methoxy-XO4–positive plaques was not as prominent as
the changes observed when both diffuse and compact deposits
were analyzed altogether (Fig S5). To complete this analysis, we
determined the concentrations of Aβ40 and Aβ42 in the TBS and
formic acid (FA) fractions of the brains, and we observed a general
decrease in the amounts of Aβ species in APP/PSEN1/APOEnull mice
as compared with APP/PSEN1 (Fig 4E–G; P = 0.0169 and P < 0.0001,
respectively, for TBS soluble Aβ40 and Aβ42; P = 0.0004 and P = 0.019,
respectively, for FA soluble Aβ40 and Aβ42). Interestingly, these
differences were essentially due to the substantial levels of am-
yloid peptides in aged APP/PSEN1 animals (Fig S6A–C), whereas the
amounts of both soluble and insoluble Aβ40/42 were comparable
between the adult cohorts (for which the lack of APOE alleviates Aβ-
dependent neuronal dysfunction). These data emphasize the weak
correlation that exists between the global amount of amyloid and
neuronal dysfunction and illustrate the necessity to assess
amyloid-dependent neurotoxicity from a functional perspective. No
substantial difference in the amount of amyloid pathology was
detected between adult APP/PSEN1 and APP/PSEN1/APOEnull mice
(except for the presence of dense-core neuritic plaques), even
though the absence of APOE in the later rescued the neuronal
responses to visual stimuli. These findings strengthen the rationale
for down-regulating ApoE expression as a possible therapeutic
approach to alleviate Aβ-dependent neuronal impairment.
Apoe genetic ablation does not alter the global levels of
excitatory and inhibitory neurotransmitter receptors but rescues
synaptic integrity near Aβ plaques
To determine if the functional alterations detected by recording
visually evoked neuronal responses in vivo might correlate with
changes of the levels of excitatory or inhibitory neurotransmitter
receptors at the synapse, we performed a biochemical analysis
after preparing synaptoneurosome-enriched fractions from the
cortex of adult wild-type, APOEnull, APP/PSEN1, and APP/PSEN1/
APOEnull mice (10–12 mo) (Fig S7). Overall, no significant difference
was detected in the levels of N-methyl-D-aspartate receptor 1
(NMDAR1), 2A (NMDAR2A), 2B (NMDAR2B), γ-aminobutyric acid re-
ceptors A (GABAR-A), and B (GABAR-B) between all the experimental
groups (Fig S8). These results demonstrate that the neuronal cir-
cuitry dysfunction previously observed in APP/PSEN1 mice do not
result from a global difference in the levels of excitatory or in-
hibitory synaptic markers.
Because local loss of synapses is one of the well-established
downstream effects of amyloid deposition that may participate in
network deterioration (Pozueta et al, 2013; Spires et al, 2005; Spires-
Jones & Hyman, 2014; Hong et al, 2016; Arbel-Ornath et al, 2017) and
considering that we detected a change in the aggregation state
of amyloid deposits in the cortex of APP/PSEN1/APOEnull mice,
we tested the hypothesis that the improved visual tuning ob-
served in the absence of APOE could be directly related with a
decreased local synaptotoxicity of Aβ peptides present in plaques
in those mice. Using the high-resolution imaging technique array
tomography, the density of pre- (synapsin) and post-synaptic
(PSD95) elements was determined in the cortical mantle of the
adult cohort previously imaged. For all plaque-bearing animals
(APP/PSEN1 and APP/PSEN1/APOEnull), the synaptic density in areas
of the cortex close (<10 μm) and far (>35 μm) from amyloid plaques
was independently measured. Total synapsin 1 and PSD95 puncta
were used as measurements of synaptic density in the four mouse
lines, as previously done in other similar studies (Koffie et al, 2009;
Koffie et al, 2012; Kay et al, 2013) (Fig 5A and B). A two-way ANOVA test
with distance from the plaque and genotype as variables was used
and detected a significant difference across both variables (dis-
tance from plaque: F(1,41) = 15.94, P = 0.0003; genotype: F(3,41) =
7.658, P = 0.0004). Comparison of individual groups using a Tukey’s
post hoc test revealed that a 30% synaptic loss was observed near
amyloid plaques in APP/PSEN1 mice (as previously observed [Koffie
et al, 2009] and Fig 5B), with an averaged density of PSD95 and
synapsin puncta close to plaques of 6.83 × 108 ± 2.76 × 107/mm3 and
7.24 × 108 ± 3.14 × 107/mm3, respectively, as compared with 9.99 × 108 ±
3.21 × 107 and 10.30 × 108 ± 3.26 × 107 synapses/mm3 far from
plaques (P < 0.0001). This decrease in synaptic density in the direct
vicinity of amyloid in APP/PSEN1 mice was also significant com-
pared with wild-type (9.77 × 108 ± 3.63 × 107 PSD95 puncta/mm3 and
10.82 × 108 ± 4.46 × 107 synapsin puncta/mm3; P < 0.0001) and
APOEnull (9.83 × 108 ± 2.42 × 107 PSD95 puncta/mm3 and 9.89 × 108 ±
3.54 × 107 synapsin puncta/mm3, P < 0.0001) controls. Interestingly,
no drop of the synaptic density was detected close to plaques in
APP/PSEN1/APOEnull mice (8.51 × 108 ± 76.51 × 107 PSD95 puncta/
mm3 and 9.53 × 108 ± 7.03 × 107 synapsin positive puncta/mm3),
which was significantly higher than the synaptic density measured
in the vicinity of amyloid deposits in APP/PSEN1 mice (P = 0.0345),
and comparable with wild-type and APOEnull animals. These results,
thus, imply that the presence of both Aβ and APOE is necessary to
observe synaptic collapse in AD transgenic mice and that abol-
ishing apoE expression suffices to rescue amyloid-dependent
synaptic loss and the functional impairments observed in APP/
PS1 mice. Intriguingly, when the accumulation of Aβ at the synapse
in APP/PSEN1 and APP/PSEN1/APOEnull was measured as the
percentage of pre- and post-synaptic densities co-localizing with
amyloid, no significant difference could be observed between those
groups (Fig S9A), thus challenging the concept of APOE acting as a
chaperone mediating Aβ accumulation at the synapse. In addition,
the synaptic volume decreased significantly close to plaques in
APP/PSEN1 mice, a parameter that remained unchanged in the
absence of APOE (Fig S9B).
The absence of APOE decreases Aβ-associated neuritic anomalies
and glial reactivity
To complete our evaluation of the impact of APOE on Aβ-dependent
neurotoxic effects in the microenvironment of amyloid plaques, we
performed a stereological analysis of the density of neuritic dys-
trophies around each deposit (Fig 5C) and Aβ-dependent glia re-
activity in the cortex of APP/PSEN1 and APP/PSEN1/APOEnull
animals (adult cohort). Although numerous abnormal neurites
were generally associated with amyloid plaques in APP/PSEN1
mice, they were seldom in APP/PSEN1/APOEnull animals (Fig 5D,
P = 0.043). In addition, when we evaluated the number of reactive
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astrocytes (Glial fibrillary acidic protein, GFAP, positive) andmicroglia
(Iba1 positive) clustered around amyloid aggregates in APP/PSEN1
and APP/PSEN1/APOEnull mice, we observed a significant decreased
density of both glial cell types in animals lacking APOE (Fig 6, P =
0.0006 for microglia and P = 0.0012 for astrocytes). These results not
only establish APOE as an essential modulator of amyloid deposition
but also demonstrate its strong impact on a large panel of Aβ-
associated neurotoxic events and downstream inflammatory re-
actions in the local vicinity of amyloid plaques. Whether or not these
effects are a direct consequence of the change in the aggregation
state and toxicity of Aβ or indirectly related to the impact of a lack of
APOE on microglia/astroglia function remains to be determined.
Discussion
Neuronal dysfunction and loss of synaptic integrity are tightly
associated with aging and AD cognitive decline, but understanding
the molecular bases of those changes and identifying possible
modulators remain as important challenges to overcome. APOE, the
major apolipoprotein of the brain and most important genetic
contributor to the sporadic form of AD (Wisniewski & Frangione,
1992; Corder et al, 1993, 1994; West et al, 1994; Hyman et al, 1996;
Lippa et al, 1997), is a well-established partner of amyloid β pep-
tides and has been shown to directly impact the aggregation,
deposition, and clearance of those neurotoxic species (Holtzman
et al, 2000; Fagan et al, 2002; Deane et al, 2008; Castellano et al, 2011;
Hashimoto et al, 2012; Koffie et al, 2012; Hudry et al, 2013). Although
those findings clearly emphasize the pivotal role of APOE in AD
neuropathological changes, the field is still divided as to whether or
not clinical benefit could be achieved by reducing the levels of
APOE (Koldamova et al, 2005; Bien-Ly et al, 2012; Liao et al, 2014;
Lane-Donovan et al, 2016; Zheng et al, 2017). In addition, previous
studies have described that a complete lack of APOE in a physi-
ological context may lead to a loss of brain function during aging.
The question, therefore, is how can we disambiguate the function of
APOE in maintaining brain resilience during aging while also
participating in Aβ-induced neurotoxicity?
By recording visually evoked neuronal responses in awake mice,
we were able to demonstrate that a complete absence of APOE
restores neuronal function in adult APP/PSEN1 animals (decreased
“off-responding” cells and increased OSI and DSI), so that the
efficacy of induced responses is comparable between wild-type
and APP/PSEN1/APOEnull animals. In addition, the lack of APOE in
AD mice preserves synaptic and neuritic integrity around plaques
and decreases amyloid-associated glial immunoreactivity. Despite
these beneficial effects, the idea of knocking-down APOE expres-
sion to improve AD neuropathological hallmarks remains contro-
versial because previous reports have shown that APOEnull animals
present with some cognitive deficits, electrophysiological alter-
ations, and functional connectivity changes when compared with
wild-type mice (Masliah et al, 1997; Kitamura et al, 2004; Trommer
et al, 2004; Yang et al, 2011a; Zerbi et al, 2014). Here, we confirm that
genetic ablation of APOE impairs visually evoked responses of aged
APOEnull and APP/PSEN1/APOEnull mice as compared with controls.
Taken together, we demonstrate that apoE genetic disruption al-
leviates Aβ-associated neurotoxicity early but sensitizes the brain
towards age-dependent neuronal dysfunction. Discrepancy be-
tween our results and previous reports may result from the ex-
perimental settings used, as we assessed neuronal function using a
relatively simple sensory circuit within the brain as compared with
more complex behavioral tasks.
Data in the human population are essentially missing, with only
one case study published so far reporting “below-average” cog-
nition and memory performances in an individual with a complete
lack of APOE protein in the brain (Cullum & Weiner, 2015). Because
of the relatively young age of the individual, it is hard to predict if
Figure 6. Decreased glial reactivity in APP/PSEN1
mice lacking APOE.
(A) RepreseAPP/PSEN1 and APP/PSEN1/APOEnull adult
mice. (B) Representative images (left panel) and
stereological evaluation (right panel) of the density of
GFAP-positive astrocytes (green) around amyloid
deposits (red, after staining using a rabbit anti-Aβ
antibody, IBL) in APP/PSEN1 and APP/PSEN1/APOEnull
adult mice. In each case, the total number of Iba-
1–positive microglia or GFAP-positive astrocytes
present in less than 50 μm around a plaque was
reported to the surface of the plaque. Scale bar =
100 μm. n = 7 mice/group (10–12 mo “adult” cohort);
Mann–Whitney test. *P < 0.005, **P < 0.001.
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the absence of APOE will lead to exacerbated cognitive decline later
on, similar to what is observed in animal models. Alternative
strategies to inhibit the detrimental impact of APOE in disease while
preserving its physiological role in maintaining brain homeostasis
have already been attempted. For example, intraperitoneal in-
jections of Aβ12-58P, a modified Aβ peptide homologous to the
binding side of APOE on Aβ40/Aβ42 peptides that crosses the
blood–brain barrier, is able to disrupt the interaction between APOE
and Aβ, reduce the formation of fibrillar aggregates, alleviate τ
pathology in triple transgenic mice (PS1M146V, APPSwe, and tau-
P30IL), and improve behavioral deficits (Yang et al, 2011b; Liu et al,
2014). Reducing the amount of APOE specifically in the brain tissue
(and not in the periphery) could be another alternative. The recent
characterization of the bEKO mouse model by Lane-Donovan and
colleagues (Lane-Donovan et al, 2016), which fortuitously lacks
APOE in the brain but shows normal levels in the plasma, suggests
that this may be the case, as these animals do not show any
cognitive deficits as compared with APOEnull mice. However, the
clinical translation of this discovery may prove difficult to achieve
considering that various neural cell types express APOE (astrocytes,
microglia, and endothelial cells). Interestingly, the work by Zheng
and colleagues demonstrated that the sole deletion of APOE in
astrocytes ameliorates the spatial learning andmemory deficits of
APP/PSEN1 mice (Zheng et al, 2017), eventually suggesting that
targeting APOE in the “right cells” (assuming that APOE derived
from astrocytes, microglia, or other cells within the brain has
different biological properties and functions) may trigger clinical
improvement.
Importantly, the “rescue effect” observed in the absence of APOE
did not directly correlate with a significant change in the global
amount of amyloid pathology in the brain of our adult cohort
(assessed by conventional immunostaining or by quantification of
Aβ by ELISA), but rather with a specific decrease in dense-core
Methoxy-positive deposits in APP/PSEN1/APOEnull mice (both in
adult and aged groups). Of note, the initial load of fibrillar amyloid
at baseline is especially abundant in the model we used, the APP/
PSEN1 strain, because of the presence of the Swedish APP (KM670/
671NL) and δ9 PS1-mutated transgenes. It is, therefore, conceivable
that the impact of APOE deficiency may be less significant in other
models of amyloidopathy that only carry a mutated APP allele.
Nevertheless, the shift in the aggregation state of amyloid between
APP/PSEN1 and APP/PSEN1/APOEnull has been reported in other
studies (Bales et al, 1997; Irizarry et al, 2000a) and essentially re-
produces the morphological difference between β-pleated sheet
deposits (labeled with Thioflavin-S) mostly observed in AD patients
and diffuse plaques detected in non-demented individuals
(Dickson, 1997; Urbanc et al, 2002). This conformational change of
extracellular amyloid is relevant to the disease as fibrillary neuritic
plaques are associated with deleterious effects on the surrounding
neuropil, such as the presence of dystrophic neurites and re-
cruitment of reactive glial cells (Masliah et al, 1990; Knowles et al,
1999; Vehmas et al, 2003), which are absent around more diffuse
aggregates observed in cognitively normal individuals and in our
APP/PSEN1/APOEnull animals. The underlying mechanisms remain
incompletely understood, but in vitro and in vivo studies have
previously shown that APOE forms stable complexes with Aβ
(Naslund et al, 1995), directly co-deposits in plaques (Namba et al,
1991), modulates Aβ oligomerization (Hashimoto et al, 2012; Garai
et al, 2014), and converts amyloid protofibril to fibril (Hori et al,
2015), which all could result in the observed changes in plaque
morphology. Further comparison of the profile of Aβ oligomers,
which are especially concentrated around amyloid plaques and
have been shown to trigger neurotoxicity (Walsh & Selkoe, 2007;
Arbel-Ornath et al, 2017; Yang et al, 2017), may give additional clues
to understand the beneficial impact the lack of ApoE on Aβ-
dependent neuronal function and synaptotoxicity.
It is possible that some of the protective effects we observed in
APP/PSEN1/APOEnull mice arise independently from the change
observed in the aggregation state of Aβ. In particular, the decreased
glial reactivity in APP/PSEN1/APOEnull mice could result from a
direct impact of APOE on the biology of microglia and astrocytes in
the context of AD, even in the presence of Aβ neurotoxic species.
The APOE-TREM2 pathway has recently been identified as a major
switch triggering a phenotypic change in microglia in the context of
neurodegeneration (Atagi et al, 2015; Yeh et al, 2016; Krasemann
et al, 2017). Upon activation of this cascade, microglial cells become
chronically inflammatory and lose their homeostatic signature, a
phenomenon that is not present when the endogenous expression
of apoe was shut down specifically in microglia. Considering that
activated neuroinflammatory microglia have also been shown to
control the conversion of resting (A2) to reactive astrocytes (A1)
(Liddelow et al, 2017), the inhibition of the TREM2-APOE pathway in
APP/PSEN1/APOEnull mice could explain the overall decrease of
glial reactivity independently of the decreased density of neuritic
plaques in those mice.
Finally, our array tomography data emphasize the importance of
APOE in driving Aβ-associated synapse loss. While the density of
synapsin and PSD95 puncta was dramatically reduced in the vicinity
of amyloid deposits in APP/PSEN1 mice (by about 30%, as we have
previously reported [Koffie et al, 2009; Kay et al, 2013]), no such
reduction of pre- or post-synaptic elements was detected in APP/
PSEN1/APOEnull mice. Still, the lack of APOE neither prevented the
recruitment of Aβ at the synapse and nor the decreased synaptic
volume characteristic of amyloidosis mouse models. As the syn-
aptic size is generally accepted as an indicator of connection
strength (Kasai et al, 2010; Penzes et al, 2011), it is possible that
synaptic stability remains compromised in APP/PSEN1/APOEnull
mice. In addition, we have previously reported that the different
APOE isoforms differentially modulate the recruitment of Aβ at the
synapse in human AD brains (Koffie et al, 2012), therefore acting as a
chaperone toward neurotoxic amyloid peptides. The fact that Aβ
still co-localizes with synaptic terminals in the absence of APOE
implies that other factors may be involved to shuttle those neu-
rotoxic species at the synapse. Among others, apolipoprotein J
(ApoJ, or clusterin) is a likely candidate, as it is also known to in-
teract with Aβ and modify its aggregation and deposition (Mulder
et al, 2014; Miners et al, 2017). Whether or not this is the case remains
to be determined, as we did observe a rescue of neuronal function
in the absence of APOE alone, therefore indicating that the pres-
ence of Aβ at the synapse is necessary but not sufficient to trigger
synaptic collapse. Because our findings place APOE as a pivotal
factor triggering amyloid synaptotoxicity, it is possible that its
association with Aβ is necessary for it to adopt a toxic conformation
or allows the interaction between Aβ and specific cellular receptors
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(such as APP itself, as recently reported [Wang et al, 2017], TREM2
[Yeh et al, 2016], or any other APOE receptors [Holtzman et al, 2012;
Lane-Donovan & Herz, 2017]) to initiate various deleterious mo-
lecular cascades in neurons or even in glial cells.
Materials and Methods
Animals
APPswe/PS1dE9 (APP/PSEN1) mice (The Jackson Laboratory
[Jankowsky et al, 2004; Reiserer et al, 2007]) were used for the study.
This mousemodel expresses the humanmutant APP and presenilin
genes respectively containing the Swedish mutation K594N/M595L
and the exon 9 deletion. Amyloid deposition starts as early as 3-mo
old in this model, with most amyloid plaques being of fibrillar
nature because of the presence of the ΔE9 PS1 mutation leading to
an increase in Aβ42/40 ratio. To generate APP/PSEN1/APOEnull
mice, one APP/PSEN1 hemizygous transgenic animal was crossed
with an APOEnull breeder (The Jackson Laboratory). The resulting
APP/PSEN1/APOE+/− offspring was then crossed with another
APOEnull breeder to generate APP/PSEN1/APOEnull and APOEnull
animals. The resulting APP/PSEN1/APOEnull offspring was then bred
with APOEnull mice to generate all the animals used in this study.
Controls included littermates from the APP/PSEN1 colony alto-
gether with C57BL/6 (appropriate controls of the APOEnull mice). We
had previously verified that these control groups showed similar
responses to visual stimulation and, therefore, could be merged
together. Genotyping for APOE and APP were performed by PCR
following the protocol given by The Jackson’s Laboratory. A detailed
description of the cohort is presented in Fig S1. All animal exper-
iments were approved by the Massachusetts General Hospital
Subcommittee on Research Animal Care following the guidelines
set forth by the National Institutes of Health Guide for the Care and
Use of Laboratory Animals.
Viral vector construction and production
The yellow cameleon cDNA (YC3.6) was cloned to an AAV2 backbone,
under a hybrid CMV immediate-early enhancer/chicken β-actin
promoter/exon1/intron and before the woodchuck hepatitis virus
posttranscriptional regulatory element (WPRE). High titers of AAV
serotype 8 were produced using a conventional triple transfection
approach by the PENN Vector Core (University of Pennsylvania).
Viruses were tittered by quantitative PCR, and the final concen-
trations of the AAV viral stocks used for this study reached 4 × 1012
vg/ml.
Intracortical AAV injection and cranial window implantation
Surgical procedures were performed as described previously
(Hudry et al, 2010; Kuchibhotla et al, 2014; Arbel-Ornath et al, 2017),
with minor modifications. Mice were anesthetized by in-
traperitoneal injection of ketamine/xylazine (100 mg/kg and 50
mg/kg, respectively, body weight) and positioned on a stereotactic
frame (Kopf Instruments). A 3-mm cranial window was opened
above the right primary visual cortex V1 (coordinates from
λ: +0.5 mm anteroposterior, 2.7 mm lateral, and 0.6 mm dorso-
ventral). After removing the skull, 3 μl (1.2 × 1010 vg) of AAV8-CBA-
YC3.6 viral suspension was injected at a rate of 0.15 μl/minute in the
layer 2/3 neurons using a 33-gauge sharp needle attached to a 10-μl
Hamilton syringe (Hamilton Medical). The window was then closed
with a 5-mm-diameter cover glass and secured with a mixture of
dental cement and Krazy Glue. A custom-made stainless steel
headpost (Ponoko) was finally fixed to the skull using C&B
Metabond dental cement (Parkell) to allow recording in awake
mice. After a recovery period of one month, the mice were habit-
uated to the head-fixation device (Thorlabs posts and Altos head
clamps) by running freely on a circular treadmill (Ponoko) for 15min
a week before the first imaging.
Recording of visually evoked neuronal responses
For in vivo calcium imaging, an Olympus FluoView FV1000MPE
multiphoton laser scanning system mounted on an Olympus
BX61WI microscope and an Olympus 25× dipping objective (NA =
1.05, Olympus) were used, with the emission path shielded from
external light contamination. A DeepSee Mai Tai Ti:sapphire mode-
locked laser (Mai Tai; Spectra-Physics) generated two-photon ex-
citation at 860 nm, and detectors containing three photomultiplier
tubes (Hamamatsu) collected emitted light in the range of 460–500,
520–560, and 575–630 nm. CFP and YFP photomultipliers (PMTs)
settings remained unchanged throughout the different imaging
sessions, but laser power was adjusted as needed. The mice were
imaged awake and directly placed under the objective. To detect
visually evoked neuronal responses, time courses of calcium tran-
sients were recorded in head-fixed awake animals while a 19-inch
LCD monitor (Viewsonic VP930B) displayed the visual stimuli in front
of the left eye (screen–eye distance, ~20 cm; screen-midline angle,
60°). Visual stimuli were drifting (2 Hz) sine-wave gratings (80 or 100%
contrast, black and white) presented for 7 s. Eight stimuli (at 45°
orientation increments) were presented sequentially in counter-
clockwise order with a 7-s pause between stimuli, and 10 cycles of
visual stimulation were presented during each recording. For each
imaging session, two to three cortical frames (254 μm × 254 μm, scan
rate 2.3 Hz, 0.429 s/frame, depth of 200–300 μm) were taken.
Image processing and analysis
In vivo imaging data were analyzed using custom-written scripts in
Fiji (National Institutes of Health: http://fiji.sc/) and MATLAB
(MathWorks). Images were aligned for shifts in the x–y plane using
the StackReg function of Fiji, neuronal cell bodies (identified by the
presence of neuritic processes) were manually selected (ROIs), YFP:
CFP ratios were created and spatially filtered, and raw time courses
were extracted. “Responsive” cells were detected by comparing the
change in directional response (ΔR; R − Rnonstimulated) across
directions and against background, and (P < 0.05, ANOVA with the
Tukey–Cramer post hoc test and Bonferonni correction). Only re-
sponsive cells were used for further analysis of orientation and
direction tuning. The OSI and DSI were calculated as described
previously (Kuchibhotla et al, 2014). In short, OSI was calculated as
the maximum directional response, ΔRmax, and divided by the sum
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of responses in all other directions, ΣΔRother (0 ≤ OSI ≤ 1; 1 =
perfectly orientation-tuned). DSI was calculated as ΔRmax divided
by the sum of that direction and the antiparallel direction, ΔRmaxr+
ΔRorthogonal (0 ≤ DSI ≤ 1; 1 = perfectly direction-tuned). The higher
the values for OSI and DSI, the better the neuron tuned to a specific
visual stimulus.
Tissue collection and processing
Mice were euthanized by CO2 asphyxiation and tissue collected for
immunohistochemical and biochemical analysis. For the mice that
underwent in vivo imaging, the right hemisphere (containing the
surgical site) was fixed by immersion in 4% paraformaldehyde and
15% glycerol in PBS for 48 h before cryoprotection with 30% glycerol
in PBS. A few 1-mm3 pieces of tissue were cut across the left
hemisphere for array tomography. Because the surgical procedure
and the injection of AAV-CBA-YC could have compromised the
results of our stereological analyses, another cohort of APP/PSEN1
and APP/PSEN1/APOEnull mice was used to perform the stereo-
logical work (right hemisphere) and the isolation of synapto-
neurosomes (from the left hemisphere directly snap-frozen in
liquid nitrogen and stored at −80°C). Additional mice were eu-
thanized to perform the sequential brain extraction from cortices.
Synaptoneurosomes preparation and Western blotting
Synaptoneurosome preparations were based on procedures de-
scribed by Tai et al (2012) withminormodifications. Briefly, an entire
mouse hemisphere (about 250 mg of frozen tissue, without cere-
bellum and olfactory bulbs) was homogenized in 1.2-ml cold Buffer
A (25 mM Tris, pH 7.5, 120 mMNaCl, 5 mM KCl, 1 mMMgCl2, 2 mM CaCl2,
1 mM dithiothreitol, and Complete protease inhibitors; Roche),
before being filtered through 80-μm nylon filters (Millipore). An
aliquot of the filtrate was supplemented with SDS to 1%, boiled for 5
min, and centrifuged at 15,000 g for 15 min, and the supernatant was
collected as total extract. The other portion was further filtered
through 5-μm pore filters (PALL Acrodisc) and centrifuged at 1,000 g
for 10 min at 4°C to pellet synaptoneurosomes. The supernatant,
corresponding to the cytosolic extract, was further centrifuged at
100,000 g for 20 min to remove microsomes or other extracellular
vesicles. The synaptoneurosome pellet was washed once with cold
Buffer A and centrifuged again at 1,000 g for 10 min. The pellet was
extracted with 0.5 ml Buffer B (50 mM Tris, pH 7.5, 1% SDS, and 2 mM
dithiothreitol) and boiled for 5 min. After centrifugation at 15,000 g
for 15 min, the supernatant was collected as synaptoneurosomal
extract. Protein content was measured by BCA assay (Pierce). The
protein concentration was adjusted to 10 μg/10 μl for all Western
blot samples, including Laemmli blue buffer and reducing agent.
The samples were electrophoresed on 4–12% Bis-Tris gels in MES
running buffer (Invitrogen). After transferring on nitrocellulose
membrane (GE Healthcare), the blots were blocked for 1 h at RT in
Odyssey Blocking Buffer (Li-Cor), before probing the membranes
overnight at 4°C with the primary antibodies diluted in blocking
buffer (1:1,000, Table 1). Incubation with IRDye 800CW or IRDye
680CW secondary antibodies (Li-Cor) followed (1:2,000) before
detection of the near infrared signals using an Odissey CLx imager
system (Li-Cor). Signal intensity was measured by densitometry
using the Integrated Density function of Fiji software (http://fiji.sc/)
and divided to GAPDH signal intensity. The samples from each
batch of SNS were first normalized to the signal observed in the
controls (Littermates), before performing statistical analyses on all
SNS preparations.
Sequential brain extraction
Sequential brain extraction was performed as described previously
(Hashimoto et al, 2012) from one cerebral hemisphere, after dis-
section of the olfactory bulb and cerebellum. The tissue was initially
homogenized in 10 volumes of TBSI (Tris-buffered saline with pro-
tease inhibitor cocktail; Roche) with 25 strokes on a mechanical
Dounce homogenizer and centrifuged at 100,000 g for 30 min at 4°C.
The supernatant was collected as TBS-soluble fraction. The resulting
pellet was consecutively extracted with TBS buffers containing 2%
Triton and 2% SDS (with protease inhibitors), alternating homoge-
nization andultracentrifugation steps (100,000 g for 30min). The final
pellet was solubilized in 500 μl of FA by sonication. After a final
ultracentrifugation step, the FA-soluble fraction was desiccated and
the pellet resuspended in 100 μl of DMSO. The content in the most
soluble (TBS) and insoluble (FA) Aβ species was analyzed in this
study. The concentrations of Aβ40, Aβ42, and Aβ oligomers were
respectively quantified with a mouse/human ELISA kit (Wako) and a
human Amyloid β oligomers (82E1-specific) assay (IBL international).
Immunohistology
After cryoprotection of the brain in 30% glycerol for 48 h, 40-μm-thick
floating sections were cut on a freezing microtome in the sagittal
plane. Floating sections were successfully permeabilized in 0.5%
Triton in TBS for 30min, blocked in 5% normal goat serum in TBS for 1
h, and incubated with primary antibody overnight at 4°C in 2.5% NGS
and 0.1% Triton in TBS (see Table 1 for a complete list of primary
antibodies used). The sections were then washed with TBS and in-
cubated with appropriate Alexa-Fluor 488– or Alexa-Fluor 568–
conjugated secondary antibodies diluted in 2.5% NGS and 0.1%
TritonX in TBS. After another round of washing, the sections were
mounted onto slides and coverslipped with VECTASHIELD Mounting
Medium with DAPI (Vector Labs). For the counterstaining of amyloid
withMethoxy-XO4, the floating sectionswere incubated for 15min in a
solution of 1 μg/ml of Methoxy-XO4 (diluted in TBS) before mounting
the slices with Fluoromount-G (No DAPI, SouthernBiotech).
Stereology-based quantitative analyses
All pathology quantification was carried out blinded until the
last statistical analyses. Stereology-based studies of amyloid-
associated neuritic dystrophies, reactive astrocytes, andmicroglia
were performed on immunolabeled sections using an Olympus
BX52 epifluorescent microscope equipped with motorized stage,
DP70 digital CCD camera, and CAST stereology software (Olympus).
The cortex was outlined under low-power objective (4×), and
dystrophies, astrocytes, and microglia counts were made using 20×
high numerical aperture (1.2) objective. Using a meander sampling
of 70% of cortical area, images were captured each time an amyloid
deposit was encountered. Those images were then analyzed using
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Fiji, counting the number of GFAP-positive astrocytes, Iba1-positive
microglial cells or neuritic dystrophies (visible after immuno-
staining for neurofilaments) close to a plaque (<50 μm) and
reporting this number to the surface of the plaque considered. For
the quantification of amyloid load and amyloid density, Alexa-568-
anti-Amyloid and Methoxy-XO4–positive plaques were imaged
using a NanoZoomer-XR digital slide scanner (Hamamatsu) under
a ×20 objective. After conversion of the .ndpis files to tiff format, the
number of deposits and their surface were determined using a
custom-written script based on the “Analyze particle” function of
Fiji (National Institutes of Health: http://fiji.sc/). The total surface
occupied by amyloid and the total number of plaques were then
reported to the cortical area of each section considered.
Array tomography
Sample collection and tissue processing
Array tomography analyses were performed as previously de-
scribed (Hudry et al, 2013; Kay et al, 2013). Five to six pieces of
cortical tissue (1 mm3) were dissected and fixed for 3 h in 4%
paraformaldehyde and 2.5% sucrose in 0.01 M PBS. After de-
hydration in ethanol, the samples were incubated in LR White resin
(Electron Microscopy Sciences) overnight at 4°C before polymeri-
zation at 53°C. Ribbons of 20–40 ultrathin (70 nm thick) serial
sections were cut with a Histo Jumbo diamond knife (Diatome) on
an ultracut microtome (Leica) and mounted on glass coverslips.
Staining and imaging
Ribbons were incubated in glycine (50 mM glycine in 1× TBS) for
5 min and blocked in blocking solution (0.05% Tween and 0.1% fish
gelatin [Sigma-Aldrich] in 1× TBS) for 1 h before antibody staining.
All antibodies (summarized in Table 1) were spun for 4 min at
10,000 g before being applied. Mouse 1C22 against oligomeric Aβ
(1:200, donated by Dominic Walsh [Yang et al, 2015], rabbit anti-
synapsin-1 (1:50, Rb X Synapsin I, AB1543P; Millipore) and guinea pig
anti-PSD95 (1:50, Anti-PSD95, 124014; Synaptic Systems [Koffie et al,
2009]) primary antibodies in block solution were added and in-
cubated at 4°C overnight. Incubation with secondary antibodies
diluted 1:50 in block solution (Alexa FluorTM 488 donkey anti-mouse
IgG [H+L], Invitrogen; Alexa FluorTM 594 donkey anti-rabbit IgG [H+
L], Invitrogen; and Alexa FluorTM 647 goat anti-guinea pig IgG [H+L],
Invitrogen) was performed for 1 h at room temperature, before
counterstaining with DAPI for 5 min. Shandon Immu-Mount
(Thermo Fisher Scientific) solution was used to mount the slides
on polysine microscope slides (VWR International). Serial sections
of the ribbon were imaged with a Zeiss AxioImager Z2 epifluor-
escent microscope, first at 10× to obtain a tilescan of the entire
ribbon, then with a 63 × 1.4 NA Plan Apochromat objective for high-
resolution images. Images were acquired with a CoolSnap digital
camera and AxioImager software with array tomography macros
(Carl Zeiss, Ltd). In short, two distinct areas were selected on each
10× tilescan. Once the areas were selected on two serial slices of the
ribbon, the AxioImager software was able to find the same areas in
each one of the subsequent slices and image them at 63×.
Data analyses
Image stacks were aligned using ImageJ (National Institutes of Health
open software; multistackreg macro [Thevenaz et al, 1998]). ROI
(10 μm × 10 μm) were cropped on the stack near plaques (<10 μm from
the plaque edge) and far away from plaques (>35 μm from the edge of
the halo). When no plaques were present (in wild-type and APOEnull
Table 1. List of antibodies used for the study.
Antigen Species Polyclonal/Monoclonal Manufacturer Cat. No
Antibodies used for Immunohistology (IH)/WB
Aβ (N-terminal) Rabbit Polyclonal IBL/Tecan 18584
Aβ 1-12 (clone BAM10) Mouse Monoclonal Sigma-Aldrich A3981
Iba1 Rabbit Polyclonal Wako 019-19741
GFAP Mouse Monoclonal Sigma-Aldrich G3893
Neurofilament (SMI-311R) Mouse Monoclonal, IgM, IgG1 BioLegend 837801
GABA B receptor 1 Mouse Monoclonal, IgG 2a Abcam ab55051
NMDAR 1 Rabbit Monoclonal Abcam ab109182
NMDAR2B Rabbit Polyclonal Abcam ab65783
NMDAR2A Rabbit Monocloncal, IgG Millipore 04-901
GABA A receptor α1 Rabbit Polyclonal Abcam ab33299
PSD95 Rabbit Monoclonal Cell Signaling 3450S
GAPDH Mouse Monoclonal Abcam ab9484
Actin Mouse Monoclonal Sigma-Aldrich A4700
Antibodies used for array tomography
Oligomeric Aβ (1C22) Mouse Monoclonal Dr. Walsh’s lab Yang, O’Malley et al (2015)
Synapsin 1 Rabbit Polyclonal Millipore AB1543P
PSD95 Guinea-pig Polyclonal Synaptic Systems 124014
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mice), ROI were randomly selected on the stack. Custom algorithms
were used to threshold the crops in IMAGEJ/FIJI (Schindelin et al, 2012).
Custom MATLAB macros were used to remove puncta that were only
found in a single section, detect synapses, quantify the numbers and
sizes of synaptic puncta, and determine which synaptic puncta were
co-localized with Aβ. Synaptic density was calculated as the number of
puncta per volume of tissue sampled (synapses/mm3).
Statistical analyses
A detailed summary of the statistical analyses performed is pre-
sented in the Supplemental Information 1 “Statistical analyses,”
including the test chosen for each analysis, exact P-values and
confidence intervals. The statistical software SAS was used to
analyze the relationship between adjusted DSI/OSI and genotype,
age, and the interaction between them. A linear mixed model was
fitted to the DSI and OSI values after log transformation, with these
factors (genotype or age) as fixed effects and mouse as random
effect. Significance was set for P-values < 0.05.
Array tomography data were analyzed using GraphPad Prism
software, and P < 0.05 was considered significant. Shapiro–Wilk test
was used to check for normal distribution of data. Brown–Forsythe
test (with ANOVA or the nonparametric equivalent Kruskal–Wallis
test) and F-test (with t test or the nonparametric equivalent
Mann–Whitney test) were used to check for equality of variance of
the data. Synaptic density in crops was measured and averaged for
each mouse. A two-way ANOVA test followed by a Tukey’s multiple
comparisons post hoc test was used to compare synaptic density
using distance from plaques and mouse genotype as the two
variables. A t test was used to compare the percentage of 1C22 co-
localizing at synapses close to plaques in APP and APP/APOEnull
mice. One-way ANOVA test (or the nonparametric equivalent
Kruskal–Wallis test) followed by a Holm Sidak’s or a Tukey’s mul-
tiple comparisons post hoc tests and t test (or the nonparametric
equivalent Mann–Whitney test) were used to compare synaptic
volume across genotypes far and close from plaques.
All the other results (stereology, Western blotting) were analyzed
using GraphPad software. Normality was initially validated using the
D’Agostino and Pearson omnibus normality test. Difference between
each group was tested using a one-way ANOVA (in case of normality)
or a Kruskal–Wallis test (non-normal distribution) followed by with
post hoc Dunn’s multiple comparison test. In case of comparisons
between two groups only (APP/PSEN1 and APP/PSEN1/APOEnull), a
conventional t test (normality) or a Mann–Whitney test (non-normal
distribution) was performed. Data are presented as mean ± SD.
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
201900325.
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